BFRI Company Profile and Key Details

Biofrontera Inc. has 10.67 million shares outstanding. The public float is 8.26 million shares, elevated short interest at 1.14% of float. This equals 118.36 thousand shares. The short ratio is 1.11 days. Institutional investors hold 25.12% of the float. Insiders own 12.74%. Leffler Eugene Frederick holds 100.00 thousand shares, Luebbert Hermann has 95.42 thousand shares and Monaco Erica L. has 76.34 thousand shares.

BFRI has shown mixed momentum, gaining 4.8% over the past week and -13.15% over the past quarter, though year-to-date performance is up 46.28%. Short-term trend indicators are mixed aligned (SMA20 7.71%, SMA50 11.61%, SMA200 8.8%). The stock’s 14-day RSI is 57.52 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.12% below its high and over 72.91% above its low. Average 10-day trading volume of 133.49 thousand shares is below the 3-month average of 403.54 thousand, indicating normal recent market interest.

Biofrontera Inc. generated EPS of -$1.82 over the past year. Five-year average earnings growth is 29.2%. The latest quarter delivered EPS of $0.50. The next quarter is forecast at $0.20. Next year's EPS is expected at $81.54. Biofrontera Inc. earnings surprise history is a mixed track record. The quarter that ended March 19, 2026, missed forecasts by 72.41%. The prior quarter beat by -1.67%. Over the last six quarters, Apple has recorded several small beats. These include 17.81% in November 13, 2024.

The stock is currently mid-range between its 52-week high and low $0.54 and $1.19. With a market capitalization of about $12.58 million, Biofrontera Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.64). Key stats such as the average daily volume over the past year has been around 381.01 thousand shares, volume is running light vs its 52-week average. Headquartered in Woburn, MA, Biofrontera Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Hermann Luebbert, the company employs approximately 92 people and listed since October 29, 2021. Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.

Biofrontera Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.27. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Biofrontera Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 12.04%, with price expected at $1.21 by May 14, 2026, within a range of $1.15 to $1.27 3-Month Outlook: Projected fall of -34.26%, reaching $0.71 by July 29, 2026, with a range of $0.61 to $0.77. 1-Year Outlook: Projected gain of 216.67%, with price at $3.42 by April 30, 2027, within a range of $1.56 to $3.38.

Biofrontera Inc. (NASDAQ:BFRI) shares are up 46.28% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Biofrontera Inc. trading at a premium to the broader market with a P/E of -1.19. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.83, suggesting 717.59% upside. Our AI forecast model points to short-term strength (12.04% over two weeks), a medium-term fall (-34.26% over three months), and a longer-term gain (216.67% over one year), with expected trading ranges indicating moderate volatility.

Biofrontera Inc. trades at a P/E ratio of -1.19, slightly below the S&P 500 average, with a price-to-sales ratio of 0.3 and a price-to-book ratio of 1.2 suggesting the stock is closer to book value. The P/FCF stands at -0.94, also above market averages.